Maternal Cannabis Exposure and Risk of ASD ADHD in Offspring: A Systematic Review of Endocannabinoid System Research
Clinical Takeaway
Children born to mothers who used cannabis during pregnancy showed a modest increase in the risk of autism spectrum disorder and a smaller increase in the risk of ADHD, based on a meta-analysis of 13 observational studies. Cannabis compounds cross the placental barrier and may affect fetal brain development through cannabinoid receptors. These findings support advising pregnant patients to avoid cannabis use, while noting that the observed risk increases are small and based on observational data.
#19 Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.
Citation: Andrade Chittaranjan. Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.. The Journal of clinical psychiatry. 2024. PMID: 39724097.
Design: 6 Journal: 0 N: 2 Recency: 1 Pop: 3 Human: 1 Risk: -2
- Preclinical only
Methodological Considerations:
- Retrospective design — selection and information bias risk
Abstract: Up to 10% of women may use cannabis during pregnancy; this is of concern because constituents of cannabis cross the placental barrier and potentially influence neurodevelopment by acting on cannabinoid receptors in the developing fetal brain. In this context, a recent meta analysis of 13 observational studies found that gestational exposure to cannabis was associated with a small increase in the risk of autism spectrum disorder (ASD; relative risk [RR], 1.30) and with an even smaller increase in the risk of attention deficit/hyperactivity disorder (ADHD; RR, 1.13); the latter finding was probably supported by publication bias. In this meta-analysis, 4 studies provided information on ASD (pooled N = 178,565) and 10 on ADHD (pooled N = 203,783). In a large (n = 222,534) retrospectively ascertained cohort study published after the meta-analysis, cannabis use disorder (CUD) recorded before pregnancy, during pregnancy, and during pregnancy plus the year after delivery were associated with closely similar increased risks of ASD (RRs, 3.02-3.21). The risks were smaller in smokers (RRs, 1.74-1.87) than in nonsmokers (RRs, 4.55-4.83) but differed little between male (RRs, 3.01-3.06) and female (RRs, 2.71-2.85) offspring. Although the cohort study had many strengths, its limitations permitted only the conclusion that peri-pregnancy exposure to CUD is associated with a large increase in the risk of ASD in offspring; it remained possible that much of the risk was driven by genetic, environmental, or behavioral variables. The field is nascent; the total number of cannabis exposed pregnancies (with ASD and ADHD as the outcomes) in world literature is small. However, cannabis use during pregnancy is, at the very least, a clear marker for adverse neurodevelopmental outcomes, besides the adverse maternal, fetal, and neonatal outcomes identified in other studies. Healthcare providers who manage women who use cannabis during pregnancy need to be aware of these adverse outcomes.
What This Study Teaches Us
Maternal cannabis use during pregnancy is associated with increased risk of autism spectrum disorder in offspring, with much larger effect sizes in studies tracking cannabis use disorder (3x-fold increase) versus self-reported smoking (1.7-1.9x increase). The strength of association differed markedly by study design and maternal smoking status, suggesting that confounding variables may account for some or much of the observed risk.
Why This Matters Clinically
Clinicians counseling pregnant women or women planning pregnancy need a clear answer about cannabis safety. This analysis suggests cannabis use during pregnancy is not benign, but the magnitude of actual causal risk remains uncertain given the observational nature of the evidence. For informed consent conversations, this provides a signal serious enough to counsel against use, even if definitive causality hasn’t been proven.
Study Snapshot
| Study Design | Meta-analysis of 13 observational studies (primarily on ASD); commentary on a large retrospective cohort study (n=222,534) published after the meta-analysis |
| Population | Meta-analysis: 178,565 pregnancies for ASD outcome, 203,783 for ADHD outcome. Cohort study: 222,534 pregnancies tracked for neurodevelopmental outcomes in offspring |
| Intervention | Maternal cannabis use during pregnancy, assessed as self-reported smoking or cannabis use disorder diagnosis. Timing varied (before, during, and peripartum periods) |
| Primary Outcome | Autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) diagnosis in offspring |
| Key Result | Meta-analysis: ASD RR 1.30, ADHD RR 1.13. Cohort study: cannabis use disorder associated with ASD RR 3.02-3.21; smaller effect in smokers (RR 1.74-1.87) than nonsmokers (RR 4.55-4.83) |
Where This Paper Deserves Skepticism
This literature remains small and entirely observational, precluding causal inference. The massive discrepancy between meta-analytic pooled estimates (RR 1.30 for ASD) and the subsequent cohort study findings (RR 3.0+) raises red flags about heterogeneity and potential confounding. Cannabis use disorder is a marker not just for cannabis exposure but for poverty, stress, other substance use, maternal psychiatric illness, and environmental instability, none of which were adequately controlled. The abstract notes that publication bias likely inflated the ADHD finding. Without randomized data or better control of confounders, we cannot distinguish active harm from correlation with unmeasured adversity.
Dr. Caplan’s Take
I read this as a serious signal that warrants counseling against cannabis in pregnancy, but I’m cautious about overstating causality. The mechanism is plausible (cannabinoid receptors do influence fetal neurodevelopment), but the epidemiology is messy. The huge gap between the meta-analysis RR of 1.3 and the cohort RR of 3+ tells me confounding is doing heavy lifting here. For my clinical conversations, I use this data to say: we don’t have proof of direct harm, but we have enough concern to recommend avoiding cannabis during pregnancy until we know more. That’s honest and actionable without overselling what we actually know.
Clinical Bottom Line
Cannabis use in pregnancy appears associated with increased autism risk, but the magnitude of true causal effect remains uncertain due to uncontrolled confounding in all available studies. Current evidence supports counseling against cannabis use in pregnancy, while acknowledging this reflects risk signal rather than proven causation.
|
Have thoughts on this? Share it:
